These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19047163)

  • 1. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
    Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
    Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
    Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
    Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
    Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
    Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
    Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
    Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
    Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumor effect of nanospheres coupled with the anti-human liver cancer monoclonal antibody HAb18].
    Kan HP; Liu ZJ; Tan YF; Lin YX; Li CF; Zhou J
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1503-5. PubMed ID: 18753092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
    Shiokawa M; Takahashi T; Murakami A; Kita S; Ito M; Sugamura K; Ishii N
    Biochem Biophys Res Commun; 2010 Sep; 399(4):733-7. PubMed ID: 20696130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
    Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
    Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
    Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
    Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
    Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
    Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.